Cell & gene therapies are headed to critical milestones

Virtual Event | 19:00 - 20:30 local time

12 December 2:00 - 3:30pm ET

Every year we wrap up a string of science conferences with a closeup at ASH on the latest R&D news covering some of biopharma’s most closely watched cell and gene therapies. And this December showcase promises to be more important as ever, as drug developers cater the favor of a sour Wall Street crowd. This year we’ll feature a fireside chat with one of the top newsmakers, followed by a panel review of the top readouts by a select group of hematology experts. And it will all be available to you, streaming online.

12 DEC

12:30 - 3:30pm ET

Virtual event

VIRTUAL EVENT

12 december 12:30 - 3:30pm ET

Expert Panel

12 Dec
12:30 - 1:30pm ET

An Endpoints News team led by managing editor Kyle Blankenship will report on all the top news out of the world’s premier cell and gene therapy science conference held virtually and in Atlanta this year. Blankenship will follow the news coverage with an online panel discussion on what topics grabbed the attention of the experts. And founding editor John Carroll will get that event started with a fireside chat involving a leading industry figure.

Mehrdad Mobasher

Mehrdad Mobasher

Chief Medical Officer, Hematology

BeiGene

Kelly Shi

Kelly Shi

Senior Biotech Equity Analyst

Jefferies LLC

Arthur Sands

Arthur Sands

President, Chief Executive Officer, and Board Director

Nurix Therapeutics

Noah Berkowitz

Noah Berkowitz

Senior Vice President, Head of Hematology Development

Bristol Myers Squibb

Robert A. Brodsky

Robert A. Brodsky

President of the American Society of Hematology

Head of Hematology at Johns Hopkins School of Medicine

Paul Schloesser

Paul Schloesser

Associate Editor

Endpoints News

Kyle LaHucik

Kyle LaHucik

Associate Editor

Endpoints News

Fireside chat

12 Dec
2:00 - 2:25pm ET

Ludovic Helfgott

Ludovic Helfgott

EVP & Head of Rare Disease

Novo Nordisk

Arsalan Arif

Arsalan Arif

Founder & Publisher

Endpoints News

Accessible, off-the-shelf CAR T: Are we close?

12 Dec
2:30 - 3:30pm ET

Since their approval five years ago, first-generation, personalized CAR Ts changed how many difficult-to-treat cancers are managed and led to positive patient outcomes. But as demand increases, so do concerns about supply limitations and time to treatment. Join us as we explore a first-of-a-kind initiative to support innovation and bring awareness to clinical trials that may ultimately lead to the availability of an off-the-shelf option for patients unable to wait for a personalized treatment.

Michael Tees

Michael Tees

Associate Member Physician, Director of the Lymphoma Program

Colorado Blood Cancer Institute

Frederick Locke

Frederick Locke

Chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy; Program Co-leader, Immuno-Oncology

Moffitt Cancer Center

Arsalan Arif

Arsalan Arif

Founder & Publisher

Endpoints News

Register

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please contact our support team.